CAS NO: | 2410512-38-6 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
Molecular Formula: C27H40N4O5;
Molecular Weight 500.63
Synonym: PCK 82;JQKD82 HCl; JQKD 82; PCK82; JQKD82; JQKD82 hydrochloride; JQKD-82; PCK-82;
In Vitro | JQKD82 (0.3 μM; 24 hours) causes an increase in the global H3K4me3 level of MM.1S cells[1]. JQKD82 (0.1-10 μM; day 1-day 5) inhibits the growth of MM.1S cells in a dose- and time-dependent manner. JQKD82 is potent at eliciting growth suppression in MM.1S cells (IC50=0.42 μM)[1]. JQKD82 (1 μM; 24 hours) induces G1 cell-cycle arrest by 48 hours in MM.1S and MOLP-8 cells[1]. |
---|---|
In Vivo | JQKD82 (50-75 mg/kg; i.p.; twice a day for 3 weeks) has anti-multiple myeloma activity[1]. JQKD82 displayed an increase in H3K4me3 levels and results in a dramatic reduction of MYC immuno-staining in vivo[1]. Animal Model: Six-week-old female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (bearing MOLP-8 TurboGFP-Luc cells)[1] Dosage: 50 mg/kg, 75 mg/kg Administration: i.p.; twice a day for 3 weeks Result: Significantly reduced tumor burden |